13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Addictive Disorders
Addictive disorders emerge from a complex interplay of genetic, environmental, and psychological factors, compelling individuals to persist in compulsive behaviors despite adverse consequences. While substance use disorders like alcoholism and opioid addiction are widely recognized, behavioral addictions such as gambling disorder and internet gaming disorder are increasingly acknowledged for their profound impact. Central to these disorders is a dysregulation of the brain's reward system, where repeated exposure to addictive substances or behaviors triggers neuroadaptations reinforcing continued engagement. This cycle of craving, consumption, and withdrawal perpetuates the addictive cycle, rendering abstinence challenging even amidst negative outcomes. Treatment strategies for addictive disorders vary but typically involve a blend of pharmacotherapy, psychotherapy, and behavioral interventions. Medications can aid in managing cravings and withdrawal symptoms, while therapy targets underlying psychological issues and imparts coping mechanisms for handling triggers and urges. Support groups such as Alcoholics Anonymous and Narcotics Anonymous offer crucial peer support and encouragement during the recovery process. In sum, addressing addictive disorders necessitates a comprehensive and individualized approach that considers each person's distinct needs and circumstances.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States